Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine.
Christensen R, Heitmann BL, Andersen KW, Nielsen OH, Sørensen SB, Jawhara M, Bygum A, Hvid L, Grauslund J, Wied J, Glerup H, Fredberg U, Villadsen JA, Kjær SG, Fallingborg J, Moghadd SAGR, Knudsen T, Brodersen J, Frøjk J, Dahlerup JF, Bojesen AB, Sorensen GL, Thiel S, Færgeman NJ, Brandslund I, Bennike TB, Stensballe A, Schmidt EB, Franke A, Ellinghaus D, Rosenstiel P, Raes J, Boye M, Werner L, Nielsen CL, Munk HL, Nexøe AB, Ellingsen T, Holmskov U, Kjeldsen J, Andersen V. Christensen R, et al. Among authors: fallingborg j. BMJ Open. 2018 Feb 8;8(2):e018166. doi: 10.1136/bmjopen-2017-018166. BMJ Open. 2018. PMID: 29439003 Free PMC article.
A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine.
Andersen V, Holmskov U, Sørensen SB, Jawhara M, Andersen KW, Bygum A, Hvid L, Grauslund J, Wied J, Glerup H, Fredberg U, Villadsen JA, Kjær SG, Fallingborg J, Moghadd SAGR, Knudsen T, Brodersen J, Frøjk J, Dahlerup JF, Nielsen OH, Christensen R, Bojesen AB, Sorensen GL, Thiel S, Færgeman NJ, Brandslund I, Stensballe A, Schmidt EB, Franke A, Ellinghaus D, Rosenstiel P, Raes J, Heitmann B, Boye M, Nielsen CL, Werner L, Kjeldsen J, Ellingsen T. Andersen V, et al. Among authors: fallingborg j. Nutrients. 2017 May 15;9(5):499. doi: 10.3390/nu9050499. Nutrients. 2017. PMID: 28505128 Free PMC article.
Biologic therapy in inflammatory bowel disease.
Theede K, Dahlerup JF, Fallingborg J, Hvas CL, Kjeldsen J, Munck LK, Nordgaard-Lassen I; Danish Society of Gastroenterology and Hepatology. Theede K, et al. Among authors: fallingborg j. Dan Med J. 2013 Jun;60(6):B4652. Dan Med J. 2013. PMID: 23743116 Free article.
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA. Steenholdt C, et al. Among authors: fallingborg j. Gut. 2014 Jun;63(6):919-27. doi: 10.1136/gutjnl-2013-305279. Epub 2013 Jul 22. Gut. 2014. PMID: 23878167 Clinical Trial.
Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes.
Julsgaard M, Hvas CL, Gearry RB, Gibson PR, Fallingborg J, Sparrow MP, Bibby BM, Connell WR, Brown SJ, Kamm MA, Lawrance IC, Vestergaard T, Svenningsen L, Baekdal M, Kammerlander H, Walsh A, Boysen T, Bampton P, Radford-Smith G, Kjeldsen J, Andrews JM, Subramaniam K, Moore GT, Jensen NM, Connor SJ, Wildt S, Wilson B, Ellard K, Christensen LA, Bell SJ. Julsgaard M, et al. Among authors: fallingborg j. Inflamm Bowel Dis. 2020 Jan 1;26(1):93-102. doi: 10.1093/ibd/izz110. Inflamm Bowel Dis. 2020. PMID: 31141607
Azathioprine treatment during lactation.
Christensen LA, Dahlerup JF, Nielsen MJ, Fallingborg JF, Schmiegelow K. Christensen LA, et al. Among authors: fallingborg jf. Aliment Pharmacol Ther. 2008 Nov 15;28(10):1209-13. doi: 10.1111/j.1365-2036.2008.03843.x. Epub 2008 Aug 30. Aliment Pharmacol Ther. 2008. PMID: 18761704 Free article.
Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab.
Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA. Steenholdt C, et al. Among authors: fallingborg j. Dig Dis Sci. 2015 Sep;60(9):2762-70. doi: 10.1007/s10620-015-3581-4. Epub 2015 Feb 12. Dig Dis Sci. 2015. PMID: 25673037 Clinical Trial.
[Mesalazine is effective in Crohn disease 1].
Fallingborg J, Langholz E, Christensen LA, Munkholm P, Dahlerup JF. Fallingborg J, et al. Ugeskr Laeger. 2005 Mar 14;167(11):1307-8; author reply 1309. Ugeskr Laeger. 2005. PMID: 15830509 Danish. No abstract available.
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravata I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Peyrin-Biroulet L; STARDUST study group. Danese S, et al. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):294-306. doi: 10.1016/S2468-1253(21)00474-X. Epub 2022 Feb 1. Lancet Gastroenterol Hepatol. 2022. PMID: 35120656 Clinical Trial.
78 results